The 8-Aminopurine Hypothesis
8-氨基嘌呤假说
基本信息
- 批准号:10038684
- 负责人:
- 金额:$ 50.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:2-AminopurineAnabolismAnimalsAntihypertensive AgentsBiochemicalBiologicalBlood CirculationBlood PressureBrain InjuriesCardiovascular DiseasesCessation of lifeChemical StructureDahl Hypertensive RatsDeoxycorticosteroneDietDiureticsExcess Dietary SaltExcretory functionFundingGuanineGuanosineHeartHypertensionHypoxanthinesInbred SHR RatsInosineKidneyLeadLongevityMediatingMetabolic syndromeMetabolismModelingOralOral AdministrationOrganPharmacologyPreventionPublishingPurine-Nucleoside PhosphorylaseRattusRenal functionSodium ChlorideStrokeSystemTestingWorkXanthine Oxidaseanalogblood pressure reductiondietary saltexperimental studyhigh salt dietimprovedin vivoinhaled nitric oxideinhibitor/antagonistinterstitialmortalityprematurepreventprotective effectsalt intakesalt sensitive hypertensionsaluretic
项目摘要
We have discovered that 8-aminoguanine (8A-Guanine), a naturally-occurring 8-aminopurine, has a unique
pharmacological profile, i.e., it exerts diuretic, natriuretic, glucosuric, antikaluretic and antihypertensive activity.
In addition, 8A-Guanine protects against target-organ damage and increases the lifespan of Dahl SS rats on a
high salt diet, an effect due to prevention of salt-induced strokes. Because 8-aminoguanosine (8A-
Guanosine) is converted to 8A-Guanine in the systemic circulation, this 8-aminopurine has similar effects to
8A-Guanine. The mechanism of action of 8A-Guanine (and 8A-Guanosine via its metabolism to 8A-Guanine) is
mostly via inhibition of purine nucleoside phosphorylase (PNPase). Importantly, in preliminary experiments we
observed that in Dahl SS rats a high salt diet (4%) reduced endogenous renal interstitial levels of 8A-
Guanosine and 8A-Guanine by 85% and 100%, respectively. These preliminary studies suggest that a high
salt intake induces 8-aminopurine deficiency, at least in Dahl SS rats; but this finding must be confirmed in
Dahl SS rats and tested in other models of hypertension. It occurred to us that 8-aminoinosine (8A-Ino) and
8-aminohypoxanthine (8A-HX) have chemical structures very similar to 8A-Guanosine and 8A-Guanine,
respectively, and are analogues of naturally-occurring inosine and hypoxanthine, respectively; therefore we
reasoned that these compounds too may be endogenous 8-aminopurines with beneficial biological activities.
Because no one has ever examined the biological effects of either 8A-Ino or 8A-HX, we conducted preliminary
renal studies with these compounds. These preliminary studies suggest that both 8A-Ino and 8A-HX may have
effects on renal function similar to those of 8A-Guanosine and 8A-Guanine, but may be even more efficacious
in this regard. However, these findings must be confirmed. Also, it is unknown: 1) whether the effects of 8A-Ino
are mediated via its metabolism to 8A-HX; 2) whether 8A-Ino and 8A-HX have antihypertensive and organ-
protective effects; 3) whether 8A-Ino and 8A-HX, like 8A-Guanosine and 8A-Guanine, are naturally-occurring;
and 4) whether their biosynthesis is also suppressed by a high salt diet. Together, our published and
preliminary findings motivate our “8-AMINOPURINE HYPOTHESIS”, which postulates that: 1) 8A-Guanosine,
8A-Guanine, 8A-Ino and 8A-HX comprise a naturally-occurring 8-aminopurine system that is
natriuretic, antihypertensive and organ-protective; 2) 8-aminopurine deficiency contributes to salt-
sensitive hypertension, target-organ damage and mortality; and 3) 8-aminopurine deficiency can be
corrected by oral treatment with 8-aminopurines. Here we propose to further test this hypothesis by: 1)
elucidating the renal effects of 8A-Ino and 8A-HX; 2) determining whether a high salt diet induces a deficiency
in all 4 8-aminopurines; and 3) determining whether 8A-Ino and 8A-HX, like 8A-Guanosine and 8A-Guanine,
have antihypertensive activity and prevent target organ damage. Finally, we will explore whether the
mechanism of action of 8A-Ino and 8A-HX involves not only inhibition of PNPase, but also of xanthine oxidase.
我们发现8-氨基鸟嘌呤(8A-鸟嘌呤)是一种天然存在的8-氨基嘌呤,具有独特的
药理学特征,即它发挥利尿、利尿钠、糖尿、抗钾尿和抗高血压活性。
此外,8A-鸟嘌呤可防止靶器官损伤并延长 Dahl SS 大鼠的寿命
高盐饮食,有预防盐引起的中风的作用。因为8-氨基鸟苷(8A-
鸟苷)在体循环中转化为 8A-鸟嘌呤,这种 8-氨基嘌呤具有与
8A-鸟嘌呤。 8A-鸟嘌呤(以及 8A-鸟苷通过代谢为 8A-鸟嘌呤)的作用机制是
主要通过抑制嘌呤核苷磷酸化酶(PNPase)。重要的是,在初步实验中我们
观察到,在 Dahl SS 大鼠中,高盐饮食 (4%) 降低了 8A- 的内源性肾间质水平
鸟苷和 8A-鸟嘌呤分别减少 85% 和 100%。这些初步研究表明,高
盐摄入会导致 8-氨基嘌呤缺乏,至少在 Dahl SS 大鼠中是如此;但这一发现必须得到证实
Dahl SS 大鼠并在其他高血压模型中进行了测试。我们想到 8-氨基肌苷 (8A-Ino) 和
8-氨基次黄嘌呤 (8A-HX) 的化学结构与 8A-鸟苷和 8A-鸟嘌呤非常相似,
分别是天然存在的肌苷和次黄嘌呤的类似物;因此我们
推断这些化合物也可能是具有有益生物活性的内源性8-氨基嘌呤。
由于没有人检查过 8A-Ino 或 8A-HX 的生物学效应,我们进行了初步研究
用这些化合物进行肾脏研究。这些初步研究表明 8A-Ino 和 8A-HX 可能具有
对肾功能的影响与 8A-鸟苷和 8A-鸟嘌呤相似,但可能更有效
在这方面。然而,这些发现必须得到证实。另外,尚不清楚:1)8A-Ino是否有效果
通过其代谢介导为 8A-HX; 2)8A-Ino和8A-HX是否具有降压和器官功能
保护作用; 3) 8A-Ino和8A-HX是否像8A-鸟苷和8A-鸟嘌呤一样是天然存在的;
4)高盐饮食是否也会抑制它们的生物合成。我们共同发布和
初步研究结果激发了我们的“8-氨基嘌呤假说”,该假说假设:1) 8A-鸟苷,
8A-鸟嘌呤、8A-Ino 和 8A-HX 组成天然存在的 8-氨基嘌呤系统
利钠、降压和器官保护; 2) 8-氨基嘌呤缺乏会导致盐-
敏感高血压、靶器官损伤和死亡率; 3) 8-氨基嘌呤缺乏症可能是
通过口服 8-氨基嘌呤治疗来纠正。在这里,我们建议通过以下方式进一步检验这一假设:1)
阐明 8A-Ino 和 8A-HX 的肾脏影响; 2)确定高盐饮食是否会导致缺乏症
全部 4 个 8-氨基嘌呤; 3) 确定 8A-Ino 和 8A-HX 是否像 8A-鸟苷和 8A-鸟嘌呤一样,
具有降压作用并防止靶器官损伤。最后,我们将探讨是否
8A-Ino和8A-HX的作用机制不仅涉及PNPase的抑制,还涉及黄嘌呤氧化酶的抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWIN Kerry JACKSON其他文献
EDWIN Kerry JACKSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWIN Kerry JACKSON', 18)}}的其他基金
The Adenosinergic Pathway in Tumor-derived Exosomes
肿瘤源性外泌体中的腺苷能途径
- 批准号:
10589774 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
The Adenosinergic Pathway in Tumor-derived Exosomes
肿瘤源性外泌体中的腺苷能途径
- 批准号:
10374743 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
相似海外基金
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10590611 - 财政年份:2022
- 资助金额:
$ 50.18万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中的骨-脂肪相互作用
- 批准号:
10706006 - 财政年份:2022
- 资助金额:
$ 50.18万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10368975 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
- 批准号:
10365254 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10202896 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
- 批准号:
10531570 - 财政年份:2021
- 资助金额:
$ 50.18万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10541847 - 财政年份:2019
- 资助金额:
$ 50.18万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10319573 - 财政年份:2019
- 资助金额:
$ 50.18万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10062790 - 财政年份:2019
- 资助金额:
$ 50.18万 - 项目类别:
Promotion of NAD+ anabolism to promote lifespan
促进NAD合成代谢以延长寿命
- 批准号:
DE170100628 - 财政年份:2017
- 资助金额:
$ 50.18万 - 项目类别:
Discovery Early Career Researcher Award